Investor Overview

Corporate Profile

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Our characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), combines proprietary product candidates with gradual, controlled up-dosing protocols to obtain meaningful desensitization to food allergens.... more >

Recent Newsmore >
September 20, 2016
Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.
— PALISADE Top-Line Results Expected in 4Q 2017 — — New RAMSES Real-World Experience Study, to Begin in 1Q 2017, Will Evaluate AR101 and Use of Potential Predictive Peanut-Specific Biomarkers Without Requiring an Oral Food Challenge for Study Entry — — Management to Host Conference Call at 5:00 p.m. ET / 2:00 p.m. PT Today — BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 20, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a b... 
August 18, 2016
Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
─ Academic Study Recently Published in the Journal of Allergy and Clinical Immunology Provides Support for Aimmune’s Planned Pediatric Trial of AR101 ─ ─ Conference Call on Monday, August 22, 2016, at 4:30 p.m. Eastern Time ─ BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 18, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for l... 
August 10, 2016
Aimmune Therapeutics Announces Second Quarter 2016 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 10, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for the second quarter of 2016. For the quarter and six months ended June 30, 2016, net loss was $18.1 million and $33.7 million, respectively, compared to a net loss of $7.4 mill... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.